Last reviewed · How we verify
Esophageal Squamous Cell Carcinoma
Approved treatments
- Tevimbra · Beigene
Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Esophageal Squamous Cell Carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Esophageal Squamous Cell Carcinoma treatment landscape brief
- Esophageal Squamous Cell Carcinoma treatment updates RSS
Frequently asked questions about Esophageal Squamous Cell Carcinoma
What drugs treat Esophageal Squamous Cell Carcinoma?
Tracked treatments include Tevimbra.
What is the treatment for Esophageal Squamous Cell Carcinoma?
Standard treatment for Esophageal Squamous Cell Carcinoma includes Tevimbra. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Esophageal Squamous Cell Carcinoma patent cliff · Esophageal Squamous Cell Carcinoma CI report
- Treatment: Tevimbra · Beigene
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing